172 related articles for article (PubMed ID: 38212905)
21. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of multiple myeloma SET domain (MMSET) is associated with advanced tumor aggressiveness and poor prognosis in serous ovarian carcinoma.
Yang S; Zhang Y; Meng F; Liu Y; Xia B; Xiao M; Xu Y; Ning X; Li H; Lou G
Biomarkers; 2013 May; 18(3):257-63. PubMed ID: 23566000
[TBL] [Abstract][Full Text] [Related]
23. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.
Ai D; Yao J; Yang F; Huo L; Chen H; Lu W; Soto LMS; Jiang M; Raso MG; Wang S; Bell D; Liu J; Wang H; Tan D; Torres-Cabala C; Gan Q; Wu Y; Albarracin C; Hung MC; Meric-Bernstam F; Wistuba II; Prieto VG; Sahin AA; Ding Q
Mod Pathol; 2021 Apr; 34(4):710-719. PubMed ID: 33011748
[TBL] [Abstract][Full Text] [Related]
24. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
25. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
26. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
[No Abstract] [Full Text] [Related]
27. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
Yang M; Xie X; Ding Y
Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
[TBL] [Abstract][Full Text] [Related]
28. Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous Carcinoma.
Yano M; Miyazawa M; Ogane N; Ogasawara A; Hasegawa K; Narahara H; Yasuda M
Anticancer Res; 2021 Mar; 41(3):1647-1654. PubMed ID: 33788761
[TBL] [Abstract][Full Text] [Related]
29. Altered expression of different GalNAc‑transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
Sheta R; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Popa I; Bachvarov D
Int J Oncol; 2017 Dec; 51(6):1887-1897. PubMed ID: 29039611
[TBL] [Abstract][Full Text] [Related]
30. Comparison of clinical behavior between mucinous ovarian carcinoma with infiltrative and expansile invasion and high-grade serous ovarian carcinoma: a retrospective analysis.
Hada T; Miyamoto M; Ishibashi H; Matsuura H; Kakimoto S; Iwahashi H; Tsuda H; Takano M
Diagn Pathol; 2022 Jan; 17(1):12. PubMed ID: 35057833
[TBL] [Abstract][Full Text] [Related]
31. Decreased Eph receptor‑A1 expression is related to grade in ovarian serous carcinoma.
Jin Y; Zou Y; Wan L; Lu M; Liu Y; Huang G; Wang J; Xi Q
Mol Med Rep; 2018 Apr; 17(4):5409-5415. PubMed ID: 29393455
[TBL] [Abstract][Full Text] [Related]
32. PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.
Ghannam-Shahbari D; Jacob E; Kakun RR; Wasserman T; Korsensky L; Sternfeld O; Kagan J; Bublik DR; Aviel-Ronen S; Levanon K; Sabo E; Larisch S; Oren M; Hershkovitz D; Perets R
Oncogene; 2018 Apr; 37(17):2213-2224. PubMed ID: 29379162
[TBL] [Abstract][Full Text] [Related]
33. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
34. Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer.
Medrano M; Communal L; Brown KR; Iwanicki M; Normand J; Paterson J; Sircoulomb F; Krzyzanowski P; Novak M; Doodnauth SA; Saiz FS; Cullis J; Al-Awar R; Neel BG; McPherson J; Drapkin R; Ailles L; Mes-Massons AM; Rottapel R
Cell Rep; 2017 Mar; 18(10):2343-2358. PubMed ID: 28273451
[TBL] [Abstract][Full Text] [Related]
35. Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer.
Song IH; Kim KR; Lim S; Kim SH; Sung CO
Pathol Res Pract; 2018 Oct; 214(10):1564-1571. PubMed ID: 30082157
[TBL] [Abstract][Full Text] [Related]
36. Novel protein and immune response markers of human serous tubal intraepithelial carcinoma of the ovary.
Gutkin DW; Shurin MR; El Azher MA; Shurin GV; Velikokhatnaya L; Prosser D; Shin N; Modugno F; Stemmer P; Elishaev E; Lokshin A
Cancer Biomark; 2019; 26(4):471-479. PubMed ID: 31658047
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
38. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
39. [Clinical significance of FOXM1 and Gli-1 protein expression in high-grade ovarian serous carcinoma].
Zhang J; Li ZY; Duan XJ; Fan XM; Liu WN; Li YH
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):904-908. PubMed ID: 27998466
[No Abstract] [Full Text] [Related]
40. Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells.
Bach AS; Derocq D; Laurent-Matha V; Montcourrier P; Sebti S; Orsetti B; Theillet C; Gongora C; Pattingre S; Ibing E; Roger P; Linares LK; Reinheckel T; Meurice G; Kaiser FJ; Gespach C; Liaudet-Coopman E
Oncotarget; 2015 Sep; 6(29):28084-103. PubMed ID: 26183398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]